The Egli lab is interested in developmental functions of the cell cycle. We are studying genome stability, DNA replication and the cell cycle in early human embryonic development, somatic cell reprogramming and differentiation to pancreatic beta cells, and learn to functionally understand the human genome. We study the earliest steps of human development to learn fundamental principles about development and differentiation.
The Eglilab is located in New York City, United States.
Follow us on Instagram and Twitter
Developmental failure of the early embryo
Spontaneous loss of the early embryo is common, preventing the formation of a normal pregnancy. Our question is what are the mechanisms that result in abnormal development and arrest. The most common cause of developmental failure in our species is cell cycle arrest and genome instability. The promise of these studies is to improve the efficiency of fertility treatments and to reduce the burden of new genetic alterations that cause abnormalities.
Understanding metabolic disease using pluripotent stem cells
An important question of cell biology are the limitations in cell proliferation of different cell types. These limitations determine size and proportions of adult organs, and the ability to regenerate. Beta cells and the cells of the pancreas have a low ability to regenerate, while stem cells have unlimited regenerative potential. What determines these differences, and how can they be exploited for therapeutic use? An important goal of these studies are to develop cell therapies for diabetes. We are now able to generate stem cells from a patient with diabetes. This might allow the treatment of diabetes with the patient's own cells.
Genome stability during cell type transitions
We are using somatic cell reprogramming to address a fundamental question of cellular biology. What keeps cells within a specific differentiated state? Our studies identify an important role of genome instability and the cell cycle as the primary obstacle to induced cell type transitions.
Cell Line Repository
We have an extensive list of various diabetes and control cell lines available in our cell line repository. Please see the Cell Line Repository Tab if you are interested in working with any of our cell lines.
If you have questions about our research, or would like to learn more, please contact us by using the contact information of the corresponding author available in one of the listed publications.
Our most recent published work:
Read the preprint by Lina Sui on bioRXiv, showing how reducing replication fork speed promotes endocrine differentiation from pluripotent stem cells and controls growth potential.
Bryan Gonzalez publishes a Letter in Cell Stem Cell on the safety of Universal Stem Cells.
Ido Sagi, Michael Zuccaro and Joao de Pinho, in a collaboration with the Benvenisty laboratory publish on human pluripotent stem cells containing only a paternal genome. Cell Stem Cell 2019. This study helps understand reproductive tumors and developmental disorders such as Prader-Willi syndrome.
PhD student and China Scholarship council scholar Shuangyu Ma publishes proof of principle on gene and cell therapy for diabetes. Read more in Stem Cell Reports
In this manuscript postdoctoral fellow Lina Sui shows that stem cells matched to a patient with type 1 diabetes, derived by somatic cell nuclear transfer, can be differentiated with high efficiency to beta cells, and can protect mice from diabetes. Read more in Diabetes.
Celebrating 20 years of human ES cells:
read more in Nature